Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

LK Schmalbrock, A Dolnik, S Cocciardi… - Blood, The Journal …, 2021 - ashpublications.org
In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …
被引用次数：119 相关文章
[PDF] academia.edu

[PDF][PDF] Clonal evolution of acute myeloid leukemia withFLT3-ITD mutation under treatment with midostaurin

LK Schmalbrock, A Dolnik, S Cocciardi, E Sträng… - blood, 2021 - academia.edu
In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

LK Schmalbrock, A Dolnik, S Cocciardi, E Sträng… - Blood, 2021 - edoc.mdc-berlin.de
In the international randomized phase III RATIFY trial, the multi-kinase inhibitor midostaurin
significantly improved overall and event-free survival in patients 18-59 years of age with …

[引用][C] Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

LK Schmalbrock, A Dolnik, S Cocciardi, E Straeng… - 2021 - repository.ubn.ru.nl
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with
midostaurin Toggle navigation Radboud Repository Toggle navigation View Item Radboud …
[HTML] nih.gov

[HTML][HTML] Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

LK Schmalbrock, A Dolnik, S Cocciardi, E Sträng… - Blood, 2021 - ncbi.nlm.nih.gov
In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …
[HTML] sciencedirect.com

[HTML][HTML] Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

LK Schmalbrock, A Dolnik, S Cocciardi, E Sträng… - Blood, 2021 - Elsevier
In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

LK Schmalbrock, A Dolnik, S Cocciardi… - …, 2021 - tobias-lib.ub.uni-tuebingen.de
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with
midostaurin Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under …

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

LK Schmalbrock, A Dolnik, S Cocciardi… - 2021 - publications.goettingen-research …
In the international randomized phase III RATIFY trial, the multi-kinase inhibitor midostaurin
significantly improved overall and event-free survival in patients 18-59 years of age with …

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

LK Schmalbrock, A Dolnik, S Cocciardi, E Straeng… - Blood, 2021 - ub01.uni-tuebingen.de
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with
midostaurin Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under …

[引用][C] Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

LK Schmalbrock, A Dolnik, S Cocciardi, E Sträng… - Blood, 2021 - oparu.uni-ulm.de
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with
midostaurin Toggle navigation English Deutsch Deutsch English Deutsch Einloggen Toggle …